FX-06

Modify Date: 2024-09-18 08:49:33

FX-06 structure	Common Name	FX-06
	CAS Number	88650-17-3	Molecular Weight	3039.41
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₃₃H₂₁₆N₄₄O₃₈	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of FX-06

FX-06 (Fibrin-derived peptide Bβ15-42) is a fibrin Bbeta chain-derived peptide. FX-06 binds to VE-cadherin and inhibits leukocyte transmigration and initiates VE-cadherin-mediated signaling. FX-06 can be used in the research of ischemia/reperfusion injury, Dengue shock syndrome (DSS)[1][2][4].

Name	FX-06

Description	FX-06 (Fibrin-derived peptide Bβ15-42) is a fibrin Bbeta chain-derived peptide. FX-06 binds to VE-cadherin and inhibits leukocyte transmigration and initiates VE-cadherin-mediated signaling. FX-06 can be used in the research of ischemia/reperfusion injury, Dengue shock syndrome (DSS)[1][2][4].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Others >> Others
In Vitro	FX-06 (50 μM, 3 days) inhibits the production of D2HG in HEK-293T cells transfected with IDH1 R132H[2].
In Vivo	FX06 (2.4 mg/kg, i.v. bolus) shows significantly improved pulmonary and circulatory function in a pig model of hemorrhagic shock and reperfusion[3]. FX06 (2.4 mg/kg, i.p., twice daily) improves survival and reduces capillary leak in mice with Dengue-induced shock[4]. FX06 (3.6 mg/kg, i.v.) protects mice from Ischemia/reperfusion (I/R)-induced kidney injury by aiding in epithelial cell proliferation and tissue repair[5]. Animal Model: Pig model of hemorrhagic shock and reperfusion [3] Dosage: 2.4 mg/kg Administration: Intravenous injection (i.v.) bolus Result: Reduced raccumulation of myeloperoxidase-pos. cells (mainly neutrophils) in myocardium, liver, and small intestine, and reduced interleukin-6 plasma levels. Animal Model: Mice with Dengue-induced shock[4] Dosage: 2.4 mg/kg Administration: Intraperitoneal injection (i.p.) Result: Significantly improved survival rates, reduced capillary leak within lungs and the intestine, and reduced hemoconcentration and fibrinogen consumption.
References	[1]. Ahrens I, et al. FX-06, a fibrin-derived Bbeta15-42 peptide for the potential treatment of reperfusion injury following myocardial infarction. Curr Opin Investig Drugs. 2009 Sep;10(9):997-1003. [2]. Zou F, et al. Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening. Bioorg Med Chem Lett. 2018 Feb 1;28(3):388-393. [3]. Roesner JP, et al. Bbeta15-42 (FX06) reduces pulmonary, myocardial, liver, and small intestine damage in a pig model of hemorrhagic shock and reperfusion. Crit Care Med. 2009 Feb;37(2):598-605. [4]. Gröger M, et al. Peptide Bbeta(15-42) preserves endothelial barrier function in shock. PLoS One. 2009;4(4):e5391. [5]. Aparna Krishnamoorthy, et al. Fibrinogen β–derived Bβ15-42 peptide protects against kidney ischemia/ reperfusion injury. Blood (2011) 118 (7): 1934–1942.

Molecular Formula	C₁₃₃H₂₁₆N₄₄O₃₈
Molecular Weight	3039.41

FX-06

Use of FX-06

Names

FX-06 Biological Activity

Chemical & Physical Properties